

ACKNOWLEDGMENTS

1. The Examiner acknowledges receipt of the amendment filed 12/21/09 wherein claims 1-3, and 7-9 were amended and claims 4, 6, and 11 were canceled.

Note: Claims 1-3, 5, and 7-9 are pending.

EXAMINER'S AMENDMENT

2. An Examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Craig Bohlken on February 18, 2010.

The application has been amended as follows.

On page 8, after line 12, insert the following.

-Brief Description of the Drawing

Figure 1 illustrates the rennin-angiotensin-aldosterone system (RAAS).-


Claim 1, line 17, delete 'optionally'.

Claim 5, line 1, replace '4' with -1-.


Replace claim 9 with the following.

9. (Currently Amended) A pharmaceutical according to claim 2 wherein L denotes a bond or a linker selected from compounds of formula $\text{NH}-(\text{CH}_2)_m-$ optionally combined with $-\text{CO}-(\text{CH}_2)_m-\text{CO}$ where m denotes a positive integer from 1 to


10, one or more units of compounds of formula (IV) wherein n is an integer from 1 to 10, or compounds of formula (VI) or (X)



Formula (IV)



Formula (VI)



Formula (X).

ALLOWABLE CLAIMS

3. Claim 1-3, 5, and 7-9 are allowable over the prior art of record. In particular, the claims are distinguished over the prior art because the prior art neither anticipates nor renders obvious pharmaceuticals having Formula I as set forth in the instant invention.

4. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably

accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to D L. Jones whose telephone number is (571)272-0617. The examiner can normally be reached on Mon.-Fri., 6:45 a.m. - 3:15 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Hartley can be reached on (571) 272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/D L. Jones/
Primary Examiner
Art Unit 1618

February 21, 2010